Search Result

Pathways Recommended:	Protein Tyrosine Kinase/RTK

Results for "

FGFR tyrosine kinases

" in MedChemExpress (MCE) Product Catalog:

By Targets:	FGFR (58) FLT3 (7) Syk (1) Akt (1) Apoptosis (4) Autophagy (3) c-Fms (3) c-Kit (15) Drug Metabolite (2) EGFR (3) ERK (1) Insulin Receptor (1) Isotope-Labeled Compounds (1) mRNA (1) PDGFR (30) Reference Standards (10) RET (8) Src (6) VEGFR (32)
By Research Areas:	Cancer (60) Cardiovascular Disease (3) Inflammation/Immunology (4) Neurological Disease (1)
Oligonucleotides:	mRNA (1)

Inhibitors & Agonists

Screening Libraries

Fluorescent Dyes

Biochemical Assay Reagents

Isotope-Labeled Compounds

Oligonucleotides

GMP Molecules

Targets Recommended: FGFR Btk Syk Pyk2 TNK1 Tyrosine Hydroxylase DYRK BRK FAK FLT3 Anaplastic lymphoma kinase (ALK)

Cat. No.	상품명	Target	연구분야	Chemical Structure

HY-10981

Lenvatinib Maximum Cited Publications 92 Publications Verification E7080	VEGFR FGFR PDGFR c-Kit RET	Cancer
Lenvatinib (E7080) is an oral, multi-targeted tyrosine kinase inhibitor that inhibits VEGFR1-3, *FGFR1-4, PDGFR, KIT, and RET*, shows potent antitumor activities .

HY-10407

SU 5402 10+ Cited Publications	VEGFR FGFR PDGFR	Cancer
SU 5402 is a potent multi-targeted receptor tyrosine kinase inhibitor with IC₅₀ of 20 nM, 30 nM, and 510 nM for VEGFR2, *FGFR1, and PDGFRβ*, respectively.

HY-12297

Sulfatinib 2 Publications Verification Surufatinib; HMPL-012	FGFR VEGFR	Cancer
Sulfatinib (Surufatinib) is a potent and highly selective tyrosine kinase inhibitor against VEGFR1/2/3, *FGFR1* and CSF1R with IC₅₀s of in a range of 1 to 24 nM.

HY-50905

Dovitinib 10+ Cited Publications CHIR-258; TKI258	FLT3 c-Kit FGFR VEGFR PDGFR c-Fms	Cancer
Dovitinib (CHIR-258) is an orally active, potent *multi-targeted tyrosine* kinase (RTK) inhibitor with IC₅₀s of 1, 2, 36, 8/9, 10/13/8, 27/210 nM for FLT3, c-Kit, CSF-1R, FGFR1/FGFR3, VEGFR1/VEGFR2/VEGFR3 and PDGFRα/PDGFRβ**, respectively. Dovitinib has potent antitumor activity .

HY-10981A

Lenvatinib mesylate Maximum Cited Publications 92 Publications Verification E7080 mesylate	VEGFR FGFR PDGFR RET c-Kit	Cancer
Lenvatinib mesylate (E7080 mesylate), an oral, multi-targeted tyrosine kinase inhibitor that inhibits VEGFR1-3, *FGFR1-4, PDGFR, KIT, and RET*, shows potent antitumor activities .

HY-16135

CEP-11981 ESK981; BOL 303213X	VEGFR FGFR	Cancer
CEP-11981(ESK981; BOL 303213X) is an orally active tyrosine kinase inhibitor (TKI), which can target TIE2, VEGFR1-3 and *FGFR1*, and has potential anti-tumor and anti-angiogenic effects .

HY-101296

PD-166866 10+ Cited Publications	FGFR Autophagy	Cancer
PD166866 is a selective *FGFR1* tyrosine kinase inhibitor with an IC₅₀ of 52.4 nM.

HY-10517

Orantinib 5+ Cited Publications SU6668; TSU-68	PDGFR FGFR VEGFR Apoptosis	Cancer
Orantinib (SU6668; TSU-68) is a multi-targeted receptor tyrosine kinase inhibitor with K_is of 2.1 μM, 8 nM and 1.2 μM for Flt-1, PDGFRβ and *FGFR1*, respectively.

HY-112452

SU11652	VEGFR FGFR PDGFR c-Kit Apoptosis	Cancer
SU11652 is a potent *receptor tyrosine* kinase (RTK)** inhibitor. SU11652 also inhibits several members of the split kinase family of RTKs, including VEGFR, *FGFR, PDGFR, and Kit*. SU11652 can be uesd for spontaneous cancers expressing Kit mutations research .

HY-10207

Dovitinib lactate 10+ Cited Publications CHIR-258 lactate; TKI-258 lactate	FLT3 c-Kit FGFR VEGFR PDGFR	Cancer
Dovitinib lactate (TKI258 lactate) is a multi-targeted tyrosine kinase inhibitor with IC₅₀s of 1, 2, 8/9, 10/13/8, 27/210 nM for FLT3, c-Kit, *FGFR1/3, VEGFR1/2/3* and PDGFRα/β, respectively .

HY-148779

FGFR3-IN-5	FGFR	Cancer
FGFR3-IN-5 is a potent and selective FGFR3 inhibitor with IC₅₀ values of 3, 44, and 289 nM for FGFR3, FGFR2, and FGFR1, respectively. FGFR3-IN-5 can be used in research of cancer .

HY-13896

PD168393 3 Publications Verification	EGFR Autophagy Apoptosis	Cancer
PD168393 is a potent, selective and cell-permeable inhibitor of EGFR tyrosine kinase and ErbB2. PD168393 irreversiblely inactivates EGF receptor ( IC₅₀=0.7 nM) and is inactive against insulin receptor, PDGFR, FGFR and PKC .

HY-100315

XL 999 tyrosine kinase-IN-1	VEGFR PDGFR FGFR	Cardiovascular Disease Cancer
XL999 is a multi-target **tyrosine kinase inhibitor. XL999 has IC₅₀ values for KDR, Flt-1, FGFR1 and PDGFRα** of 4 nM, 20 nM, 4 nM and 2 nM, respectively. XL999 can be used in the research of cancer .

HY-109082

Cevidoplenib SKI-O-703	Syk	Inflammation/Immunology
Cevidoplenib (SKI-O-703) is an orally available inhibitor of *spleen tyrosine* kinase (Syk)*, with potential anti-inflammatory and immunomodulating activities. Cevidoplenib is also the mesylate form of SKI-O-592. Cevidoplenib and SKI-O-592 inhibits BCR-mediated survival, proliferation, and differentiation of B cells. And SKI-O-592 potently inhibits multiple kinases* with IC₅₀s of 6.2 nM (Syk), 1.859 μM (Jak2), 5.807 μM (Jak3), 0.412 μM (RET), 0.687 μM (KOR), 1.783 μM (FLT3), 16.96 μM (FGFR1), 5.662 μM (FGFR3), and 0.709 μM (Pyk2), respectively .

HY-10981S

Lenvatinib-d4 E7080-d₄	VEGFR FGFR PDGFR c-Kit RET	Cancer
Lenvatinib-d₄ is the deuterium labeled Lenvatinib. Lenvatinib (E7080) is an oral, multi-targeted tyrosine kinase inhibitor that inhibits VEGFR1-3, FGFR1-4, PDGFR, KIT, and RET, shows potent antitumor activities .

HY-10185

TG 100572 Hydrochloride 3 Publications Verification	Src VEGFR FGFR PDGFR	Inflammation/Immunology
TG 100572 Hydrochloride is a multi-targeted kinase inhibitor which inhibits receptor tyrosine kinases and Src kinases; has IC₅₀s of 2, 7, 2, 16, 13, 5, 0.5, 6, 0.1, 0.4, 1, 0.2 nM for VEGFR1, VEGFR2, FGFR1, FGFR2, PDGFRβ, Fgr, Fyn, Hck, Lck, Lyn, Src, Yes, respectively.

HY-112412

PDGFR Tyrosine kinase-IN-1	PDGFR	Neurological Disease
PDGFR Tyrosine kinase-IN-1, a multikinase inhibitor, inhibits PDGFR, EGFR, FGFR, PKA, and PKC, respectively. PDGFR Tyrosine kinase-IN-1 can be used for the research of amyotrophic lateral sclerosis .

HY-10186

TG 100801 1 Publications Verification	VEGFR FGFR PDGFR Src	Cancer
TG 100801 is a proagent that generates TG 100572 by de-esterification in development to treat age-related macular degeneration. TG 100572 is a multi-targeted kinase inhibitor which inhibits receptor tyrosine kinases and Src kinases; has IC₅₀s of 2, 7, 2, 16, 13, 5, 0.5, 6, 0.1, 0.4, 1, 0.2 nM for VEGFR1, VEGFR2, *FGFR1, FGFR2, PDGFRβ, Fgr, Fyn, Hck, Lck, Lyn, Src, Yes*, respectively.

HY-10184

TG 100572	Src VEGFR PDGFR FGFR	Cancer
TG 100572 is a multi-targeted kinase inhibitor which inhibits receptor tyrosine kinases and Src kinases; has IC₅₀s of 2, 7, 2, 16, 13, 5, 0.5, 6, 0.1, 0.4, 1, 0.2 nM for VEGFR1, VEGFR2, FGFR1, FGFR2, PDGFRβ, Fgr, Fyn, Hck, Lck, Lyn, Src, Yes, respectively.

HY-10981R

Lenvatinib (Standard) E7080 (Standard)	Reference Standards VEGFR FGFR PDGFR c-Kit RET	Cancer
Lenvatinib (Standard) is the analytical standard of Lenvatinib. This product is intended for research and analytical applications. Lenvatinib (E7080) is an oral, multi-targeted tyrosine kinase inhibitor that inhibits VEGFR1-3, *FGFR1-4, PDGFR, KIT, and RET*, shows potent antitumor activities .

HY-112345

PD-089828	FGFR PDGFR EGFR Src	Cancer
PD-089828 is an ATP competitive inhibitor of *FGFR-1, PDGFR-β* and EGFR (IC₅₀s=0.15, 1.76, and 5.47 µM, respectively) and a noncompetitive inhibitor of c-Src tyrosine kinase (IC₅₀=0.18 µM). PD-089828 also inhibits MAPK with an IC₅₀ of 7.1 µM. PD-089828 inhibits PDGF-, EGF- and bFGF-mediated tyrosine kinase receptor autophosphorylation in vitro. PD-089828 has a long-lasting cellular activity .

HY-133980A

O-Demethyl Lenvatinib hydrochloride	Drug Metabolite	Cancer
O-Demethyl Lenvatinib hydrochloride is a metabolite of Lenvatinib (HY-10981). Lenvatinib (E7080) is an oral, multi-targeted tyrosine kinase inhibitor that inhibits VEGFR1-3, FGFR1-4, PDGFR, KIT, and RET. Lenvatinib shows potent antitumor activities .

HY-118203

SU4984	FGFR PDGFR Insulin Receptor	Cancer
SU4984 is a protein tyrosine kinase inhibitor, with an IC₅₀ of 10-20 μM for fibroblast growth factor receptor 1 (FGFR1). SU4984 is also inhibits platelet-derived growth factor receptor, and insulin receptor. SU4984 can be used for the research of cancer .

HY-10407G

SU 5402	VEGFR EGFR PDGFR	Cancer
SU 5402 (GMP) is SU 5402 (HY-10407) produced by using GMP guidelines. GMP small molecules work appropriately as an auxiliary reagent for cell therapy manufacture. SU 5402 is a potent multi-targeted receptor tyrosine kinase inhibitor with IC₅₀ of 20 nM, 30 nM, and 510 nM for VEGFR2, *FGFR1, and PDGFRβ*, respectively .

HY-133980

O-Demethyl Lenvatinib	Drug Metabolite	Cancer
O-Demethyl Lenvatinib is a metabolite of Lenvatinib (HY-10981). Lenvatinib (E7080) is an oral, multi-targeted tyrosine kinase inhibitor that inhibits VEGFR1-3, FGFR1-4, PDGFR, KIT, and RET, shows potent antitumor activities .

HY-B0062

Dovitinib lactate hydrate TKI258 lactate hydrate; CHIR-258 lactate hydrate	FLT3 c-Kit FGFR VEGFR PDGFR	Cancer
Dovitinib lactate hydrate (TKI258 lactate hydrate) is a multi-targeted tyrosine kinase inhibitor with IC₅₀s of 1, 2, 8/9, 10/13/8, 27/210 nM for FLT3, c-Kit, *FGFR1/3, VEGFR1/2/3* and PDGFRα/β, respectively .

HY-10187

TG 100801 Hydrochloride	VEGFR FGFR PDGFR Src	Cancer
TG 100801 Hydrochloride is a proagent that generates TG 100572 by de-esterification in development to treat age-related macular degeneration. TG 100572 is a multi-targeted kinase inhibitor which inhibits receptor tyrosine kinases and Src kinases; has IC₅₀s of 2, 7, 2, 16, 13, 5, 0.5, 6, 0.1, 0.4, 1, 0.2 nM for VEGFR1, VEGFR2, FGFR1, FGFR2, PDGFRβ, Fgr, Fyn, Hck, Lck, Lyn, Src, Yes, respectively.

HY-50905R

Dovitinib (Standard) CHIR-258 (Standard); TKI258 (Standard)	FLT3 c-Kit FGFR VEGFR PDGFR c-Fms Reference Standards	Cancer
Dovitinib (Standard) is the analytical standard of Dovitinib. This product is intended for research and analytical applications. Dovitinib (CHIR-258) is an orally active, potent multi-targeted tyrosine kinase (RTK) inhibitor with IC50s of 1, 2, 36, 8/9, 10/13/8, 27/210 nM for FLT3, c-Kit, CSF-1R, FGFR1/FGFR3, VEGFR1/VEGFR2/VEGFR3 and PDGFRα/PDGFRβ, respectively. Dovitinib has potent antitumor activity .

HY-159840

Fanregratinib	FGFR	Cancer
Fanregratinib is a fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitor .

HY-101466A

E7090 succinate	FGFR	Cancer
E7090 succinate is an orally available, selective and potent inhibitor of **FGFR1, FGFR2 and FGFR3** tyrosine kinase activities, with IC₅₀ values of 0.71 nM, 0.50 nM, 1.2 nM, and 120 nM for FGFR1/2/3/4, respectively .

HY-E70823

FGFR2 N549K Recombinant Human Active Protein Kinase	FGFR	Cancer
FGFR2 is a receptor tyrosine kinase that is involved in many human cancers such as intrahepatic cholangiocarcinomas and hepatocellular carcinomas. FGFR2 N549K is a mutant of FGFR3. FGFR2 N549K Recombinant Human Active Protein Kinase is a recombinant FGFR4 N535K protein that can be used to study FGFR4 N535K-related functions .

HY-10981S1

Lenvatinib-d5 E7080-d₅	VEGFR FGFR PDGFR c-Kit RET	Cancer
Lenvatinib-d₅ is the deuterium labeled Lenvatinib. Lenvatinib (E7080) is an oral, multi-targeted tyrosine kinase inhibitor that inhibits VEGFR1-3, FGFR1-4, PDGFR, KIT, and RET, shows potent antitumor activities .

HY-170934

BW710	FGFR	Cancer
BW710 is an orally active fibroblast growth factor receptor 2 (FGFR2) inhibitor. BW710 inhibits the proliferation of BaF3-FGFR2 cells with an IC₅₀ of 2.8 nM. BW710 abolishes *FGFR2* enzymatic activity and is selective against other 75 tyrosine kinases including *FGFR1, FGFR3, and FGFR4* at 1 μM. BW710 suppresses the *FGFR2* signaling and selectively inhibits *FGFR2*-driven cancer cell proliferation. BW710 displays reasonable pharmacokinetic properties with an oral bioavailability of 29 % in mice .

HY-10981AR

Lenvatinib mesylate (Standard) E7080 mesylate (Standard)	Reference Standards VEGFR FGFR PDGFR RET c-Kit	Cancer
Lenvatinib (mesylate) (Standard) is the analytical standard of Lenvatinib (mesylate). This product is intended for research and analytical applications. Lenvatinib mesylate (E7080 mesylate), an oral, multi-targeted tyrosine kinase inhibitor that inhibits VEGFR1-3, *FGFR1-4, PDGFR, KIT, and RET*, shows potent antitumor activities .

HY-147619

FGFR-IN-4	FGFR	Cancer
FGFR-IN-4 is a potent inhibitor of *FGFR. Fibroblast growth factor receptor (FGFR) is a tyrosine* kinase receptor that binds to fibroblast growth factor ligands. FGFR-IN-4 has the potential for the research of cancer diseases (extracted from patent WO2022033532A1, compound 20) . FGFR-IN-4 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-147620

FGFR-IN-5	FGFR	Cancer
FGFR-IN-5 is a potent inhibitor of *FGFR. Fibroblast growth factor receptor (FGFR) is a tyrosine* kinase receptor that binds to fibroblast growth factor ligands. FGFR-IN-5 has the potential for the research of cancer diseases (extracted from patent WO2022042612A1, compound 3) . FGFR-IN-5 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-50905S

Dovitinib-d8	FLT3 c-Kit FGFR VEGFR PDGFR c-Fms	Cancer
Dovitinib-d₈ is the deuterium labeled Dovitinib. Dovitinib (CHIR-258) is a multi-targeted tyrosine kinase inhibitor with IC₅₀s of 1, 2, 8/9, 10/13/8, 27/210 nM for FLT3, c-Kit, FGFR1/FGFR3, VEGFR1/VEGFR2/VEGFR3 and PDGFRα/PDGFRβ, respectively .

HY-10981S2

Lenvatinib-15N,d4 E7080-¹⁵N,d₄	VEGFR c-Kit FGFR RET PDGFR Isotope-Labeled Compounds	Cancer
Lenvatinib- ¹⁵N,d₄ is ¹⁵N and deuterated labeled Lenvatinib (HY-10981). Lenvatinib (E7080) is an oral, multi-targeted tyrosine kinase inhibitor that inhibits VEGFR1-3, *FGFR1-4, PDGFR, KIT, and RET*, shows potent antitumor activities .

HY-10207R

Dovitinib lactate (Standard) CHIR-258 lactate (Standard); TKI-258 lactate (Standard)	Reference Standards FLT3 c-Kit FGFR VEGFR PDGFR	Cancer
Dovitinib (lactate) (Standard) is the analytical standard of Dovitinib (lactate). This product is intended for research and analytical applications. Dovitinib lactate (TKI258 lactate) is a multi-targeted tyrosine kinase inhibitor with IC50s of 1, 2, 8/9, 10/13/8, 27/210 nM for FLT3, c-Kit, FGFR1/3, VEGFR1/2/3 and PDGFRα/β, respectively .

HY-E70827

FGFR2 V564L Recombinant Human Active Protein Kinase	FGFR	Cancer
FGFR2 is a receptor tyrosine kinase that is involved in many human cancers such as intrahepatic cholangiocarcinomas and hepatocellular carcinomas. FGFR2 V564L is a mutant of FGFR3. FGFR2 V564L Recombinant Human Active Protein Kinase is a recombinant FGFR2 V564L protein that can be used to study FGFR2 V564L-related functions .

HY-E70818

FGFR2 K659M Recombinant Human Active Protein Kinase	FGFR	Cancer
FGFR2 is a receptor tyrosine kinase that is involved in many human cancers such as intrahepatic cholangiocarcinomas and hepatocellular carcinomas. FGFR2 K659M is a mutant of FGFR3. FGFR2 K659M Recombinant Human Active Protein Kinase is a recombinant FGFR2 K659M protein that can be used to study FGFR2 K659M-related functions .

HY-E70825

FGFR2 V564F Recombinant Human Active Protein Kinase	FGFR	Cancer
FGFR2 is a receptor tyrosine kinase that is involved in many human cancers such as intrahepatic cholangiocarcinomas and hepatocellular carcinomas. FGFR2 V564F is a mutant of FGFR3. FGFR2 V564F Recombinant Human Active Protein Kinase is a recombinant FGFR2 V564F protein that can be used to study FGFR2 V564F-related functions .

HY-E70826

FGFR2 V564I Recombinant Human Active Protein Kinase	FGFR	Cancer
FGFR2 is a receptor tyrosine kinase that is involved in many human cancers such as intrahepatic cholangiocarcinomas and hepatocellular carcinomas. FGFR2 V564I is a mutant of FGFR3. FGFR2 V564I Recombinant Human Active Protein Kinase is a recombinant FGFR2 V564I protein that can be used to study FGFR2 V564I-related functions .

HY-E70815

FGFR2 K526E Recombinant Human Active Protein Kinase	FGFR	Cancer
FGFR2 is a receptor tyrosine kinase that is involved in many human cancers such as intrahepatic cholangiocarcinomas and hepatocellular carcinomas. FGFR2 K526E is a mutant of FGFR3. FGFR2 K526E Recombinant Human Active Protein Kinase is a recombinant FGFR2 K526E protein that can be used to study FGFR2 K526E-related functions .

HY-E70814

FGFR2 C491S Recombinant Human Active Protein Kinase	FGFR	Cancer
FGFR2 is a receptor tyrosine kinase that is involved in many human cancers such as intrahepatic cholangiocarcinomas and hepatocellular carcinomas. FGFR2 C491S is a mutant of FGFR3. FGFR2 C491S Recombinant Human Active Protein Kinase is a recombinant FGFR2 C491S protein that can be used to study FGFR2 C491S-related functions .

HY-E70822

FGFR2 N549H Recombinant Human Active Protein Kinase	FGFR	Cancer
FGFR2 is a receptor tyrosine kinase that is involved in many human cancers such as intrahepatic cholangiocarcinomas and hepatocellular carcinomas. FGFR2 N549H is a mutant of FGFR3. FGFR2 N549H Recombinant Human Active Protein Kinase is a recombinant FGFR4 N535H protein that can be used to study FGFR4 N535H-related functions .

HY-E70821

FGFR2 M537I Recombinant Human Active Protein Kinase	FGFR	Cancer
FGFR2 is a receptor tyrosine kinase that is involved in many human cancers such as intrahepatic cholangiocarcinomas and hepatocellular carcinomas. FGFR2 M537I is a mutant of FGFR3. FGFR2 M537I Recombinant Human Active Protein Kinase is a recombinant FGFR2 M537I protein that can be used to study FGFR2 M537I-related functions .

HY-E70819

FGFR2 K659N Recombinant Human Active Protein Kinase	FGFR	Cancer
FGFR2 is a receptor tyrosine kinase that is involved in many human cancers such as intrahepatic cholangiocarcinomas and hepatocellular carcinomas. FGFR2 K659N is a mutant of FGFR3. FGFR2 K659N Recombinant Human Active Protein Kinase is a recombinant FGFR2 K659N protein that can be used to study FGFR2 K659N-related functions .

HY-E70816

FGFR2 K641N Recombinant Human Active Protein Kinase	FGFR	Cancer
FGFR2 is a receptor tyrosine kinase that is involved in many human cancers such as intrahepatic cholangiocarcinomas and hepatocellular carcinomas. FGFR2 K641N is a mutant of FGFR3. FGFR2 K641N Recombinant Human Active Protein Kinase is a recombinant FGFR2 K641N protein that can be used to study FGFR2 K641N-related functions .

HY-149486

FGFR1 inhibitor 7	FGFR	Cancer
FGFR1 inhibitor 7 (compound 5) is an inhibitor of FGFR1 Tyrosine Kinase with IC₅₀ value of 0.33 nM. FGFR1 inhibitor 7 shows broad-spectrum cytotoxicity agasinst human cancer cell lines, and inhibits MOLT3 cells with IC₅₀ of 2.1 μM .

Cat. No.	상품명

HY-L016

Protein Tyrosine Kinase Compound Library

1,578 compounds

Protein tyrosine kinases (PTKs) are key signaling molecules and important drug targets. Two classes of PTKs are present in cells: the transmembrane receptor PTKs (RTKs) and the nonreceptor PTKs. The RTK family includes the receptors for insulin and for many growth factors, such as EGFR, FGFR, PDGFR, VEGFR, and NGFR. RTKs are transmembrane glycoproteins that are activated by the binding of their ligands, and they transduce the extracellular signal to the cytoplasm by phosphorylating tyrosine residues on the receptors themselves (autophosphorylation) and on downstream signaling proteins. Their principal functions of PTKs involve the regulation of multicellular aspects of the organism. Cell to cell signals concerning growth, differentiation, adhesion, motility, and death are frequently transmitted through tyrosine kinases. In humans, tyrosine kinases have been demonstrated to play significant roles in the development of many disease states, including diabetes and cancers.

MCE designs a unique collection of 1,578 compounds that act as a useful tool for PTKs-related drug screening and disease research.

Cat. No.	상품명	Chemical Structure

HY-10981S

Lenvatinib-d4
Lenvatinib-d₄ is the deuterium labeled Lenvatinib. Lenvatinib (E7080) is an oral, multi-targeted tyrosine kinase inhibitor that inhibits VEGFR1-3, FGFR1-4, PDGFR, KIT, and RET, shows potent antitumor activities .

HY-10981S1

Lenvatinib-d5
Lenvatinib-d₅ is the deuterium labeled Lenvatinib. Lenvatinib (E7080) is an oral, multi-targeted tyrosine kinase inhibitor that inhibits VEGFR1-3, FGFR1-4, PDGFR, KIT, and RET, shows potent antitumor activities .

HY-50905S

Dovitinib-d8
Dovitinib-d₈ is the deuterium labeled Dovitinib. Dovitinib (CHIR-258) is a multi-targeted tyrosine kinase inhibitor with IC₅₀s of 1, 2, 8/9, 10/13/8, 27/210 nM for FLT3, c-Kit, FGFR1/FGFR3, VEGFR1/VEGFR2/VEGFR3 and PDGFRα/PDGFRβ, respectively .

HY-10981S2

Lenvatinib-15N,d4
Lenvatinib- ¹⁵N,d₄ is ¹⁵N and deuterated labeled Lenvatinib (HY-10981). Lenvatinib (E7080) is an oral, multi-targeted tyrosine kinase inhibitor that inhibits VEGFR1-3, *FGFR1-4, PDGFR, KIT, and RET*, shows potent antitumor activities .

Cat. No.	상품명		Classification

HY-174687

Human FGFR4 mRNA		mRNA
Human FGFR4 mRNA encodes the human fibroblast growth factor receptor 4 (FGFR4) protein, a tyrosine kinase and cell surface receptor for fibroblast growth factors. FGFR4 is involved in the regulation of several pathways, including cell proliferation, cell differentiation, cell migration, lipid metabolism, bile acid biosynthesis, vitamin D metabolism, glucose uptake, and phosphate homeostasis.

Targets Recommended: FGFR Btk Syk Pyk2 TNK1 Tyrosine Hydroxylase DYRK BRK FAK FLT3 Anaplastic lymphoma kinase (ALK)

Cat. No.	상품명	Target	연구분야	Chemical Structure

HY-10407G

SU 5402	VEGFR EGFR PDGFR	Cancer
SU 5402 (GMP) is SU 5402 (HY-10407) produced by using GMP guidelines. GMP small molecules work appropriately as an auxiliary reagent for cell therapy manufacture. SU 5402 is a potent multi-targeted receptor tyrosine kinase inhibitor with IC₅₀ of 20 nM, 30 nM, and 510 nM for VEGFR2, *FGFR1, and PDGFRβ*, respectively .

온라인 문의

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
호칭			Country or Region *
고객명 *			회사명 *
Department *
메일주소 *			상품명 *
Cat. No.			Requested quantity *
전화번호 *
비고

온라인 문의

Inquiry Information

상품명:
Cat. No.:
수량:
MCE Japan Authorized Agent: